Active Ingredient(s): Alectinib
FDA Approved: * December 11, 2015
Pharm Company: * HOFFMAN-LA ROCHE
Category: Cancer

Alectinib (INN,[2] marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK)[3][4] and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Contents 1 History, clinical trials, Approvals and medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacok... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Alecensa 150 mg Oral Capsule
NDC: 50242-130
Genentech, Inc.